Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

The maker of an electrical implant that treats leg and back pain posted revenue of $101.9 million in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $98.4 million.

Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

This was also ~18% of the company's permanent implant volumes. It pulled this to another operating loss of $25.8mm and a net loss of $0.69/share, flat on Q2 FY'22.

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City… ...

Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. See why I will remain on the sidelines on NVRO stock for now.

Pain management company Nevro Corp NVRO reported Q2 FY23 revenue of $108.8 million, up 4% Y/Y, missing the management guidance of $110 million-$112 million and consensus of $109.33 million.

Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 ...

Financial Position Nevro exited second-quarter 2022 with cash and cash equivalents, and short-term investments of $310.8 million compared with $323.6 million at the end of first quarter. Long-term ...